Need to keep on high of the science and politics driving biotech immediately? Join to get our biotech e-newsletter in your inbox.
Pithy intro textual content in regards to the biopharma milieu.
Novartis cites extra tumor studies after Zolgensma
Novartis has disclosed seven beforehand unreported instances of tumors in youngsters who acquired Zolgensma, its gene remedy for spinal muscular atrophy. The corporate has acquired 9 tumor studies in all because the remedy was accepted in 2019, STAT’s Ed Silverman and Jason Mast write.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
